NICE issues final and binding yes for Celgene's Vidaza
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has today published final and binding guidance recommending Celgene's life-extending anticancer (5-azacitidine) for treating NHS patients with myelodysplastic syndromes. The positive recommendations follow a two year appraisal process and come on the back of an updated patient access scheme.